Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Enrollment for Allon Clinical Trial Hits Halfway Mark

May 19, 2011 7:09 am | News | Comments

Allon Therapeutics Inc. has updated the progress of a Phase 2/3 clinical trial that is evaluating the company's lead neuroprotective drug candidate, davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.


Japan's Takeda Buying Nycomed for $13.6 Billion

May 19, 2011 6:19 am | by Tomoko A. Hosaka, Associated Press | News | Comments

Takeda Pharmaceutical Co. said it will buy Switzerland's Nycomed for $13.6 billion, in an all-cash deal that is the largest ever overseas takeover by a Japanese pharmaceutical company.


inVentiv Health to Acquire PharmaNet

May 19, 2011 6:14 am | News | Comments

inVentiv Health announced it has signed a definitive agreement to purchase PharmaNet Development Group, extending its global presence to nearly 40 countries and enhancing both its early- and late-stage clinical development capabilities.


Antibody Microarray

May 19, 2011 5:53 am | Drug Discovery & Development | Product Releases | Comments

The QuantiPlasma Array, a monoclonal antibody microarray from Randox Pharma Services, is designed to assess the level of multiple proteins simultaneously in human plasma.


argen-x Initiates Second Preclinical Program

May 19, 2011 5:49 am | News | Comments

arGEN-X announced that  ARGX-110, a human antibody specific for an undisclosed, clinically validated cell surface receptor has moved into formal pre-clinical development, less than 18 months since beginning its operations. 


SuppreMol Licenses Interleukin 3 Antibody

May 19, 2011 5:46 am | News | Comments

SuppreMol GmbH, a biopharmaceutical company developing therapeutics for the treatment of autoimmune diseases, has agreed to in-license an antibody directed against interleukin 3 (IL-3).


Isotyping ELISA Kit

May 19, 2011 5:43 am | Drug Discovery & Development | Product Releases | Comments

A mouse monoclonal antibody (mAb) isotyping ELISA kit from Eagle Biosciences, Inc. uses a 96-well ELISA format for identification of both mouse immunoglobulin subclass and light chain.


AbD Serotec Licenses Seven Diagnostic HuCAL Antibodies

May 19, 2011 5:35 am | News | Comments

MorphoSys AG announced that Proteomika, a Spanish biotechnology company specializing in biomarker discovery, has licensed seven diagnostic HuCAL-antibodies from MorphoSys's AbD Serotec Division.


Regulus Therapeutics Expands Executive Team

May 19, 2011 5:28 am | News | Comments

Regulus Therapeutics announced the appointment of Mary Glanville as senior vice president of human capital and Christopher Aker as senior director of legal affairs and secretary.


Ludwig Institute and Polaris Explore Potential Cancer Therapy

May 19, 2011 5:22 am | News | Comments

Ludwig Institute for Cancer Research (LICR) and Polaris Group announced a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase.


Seaside Therapeutics Reviews Fragile X Syndrome Options

May 19, 2011 5:13 am | News | Comments

Seaside Therapeutics has published a review paper detailing the evolving scientific and drug development for fragile X syndrome, the most common inherited form of intellectual disability and most common known cause of autism.


Drosha Could be Target for Cervical Cancer Drug

May 19, 2011 5:08 am | News | Comments

Cancer Research UK scientists have discovered that a common gene fault in cervical cancer cells triggers a ripple of molecular signals, which makes the disease more aggressive.


Phase I/II Clinical Trial Results for Lupus Patients

May 19, 2011 5:03 am | News | Comments

Neovacs published the initial results of a phase I/II study with IFN?-Kinoid in lupus patients that highlights the safety, immunogenicity, and the pharmacodynamics of the therapy, according to a report by Neovacs.


MS Patients Show Relapse Rate Reduction in Coptimize Study

May 19, 2011 4:58 am | News | Comments

Teva Pharmaceutical reported preliminary data from two studies, Coptimize and QualiCop.


Epstein-Barr Could Be MS Risk Factor

May 18, 2011 11:54 am | News | Comments

The Epstein-Barr virus, belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus, is one of the environmental factors that might cause multiple sclerosis.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.